Satisfaction and effectiveness of switching from intravenous to subcutaneous belimumab treatment in daily clinical practice.

Beatriz Frade-Sosa Tarek Carlos Salman MonteJavier NarváezIrene PeraltaSebastian SandovalBerta MagallaresSergi HerediaNuria SapenaAnne Riveros-FrutosAlejandro OlivéHector CorominasJosefina Cortés-HernándezJosé A Gómez-Puerta

Published in: Lupus (2024)

Overall satisfaction, satisfaction with via of administration, and satisfaction with the time taken to receive BEL were higher for SQ BEL treatment. A switching SQ strategy is a reasonable alternative for BEL patients.

Keyphrases

clinical practice
end stage renal disease
randomized controlled trial
systemic lupus erythematosus
systematic review
newly diagnosed
chronic kidney disease
low dose
prognostic factors
peritoneal dialysis
high dose